{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

GEM III Survey Questionnaire

Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
  1. Please mention the factors influencing your choice of oral antidiabetic drugs for a newly diagnosed type 2 diabetes? *
  2. What are your primary treatment goals for T2DM patients? (Select all that apply) *

  3. How often do you monitor HbA1c levels in your T2DM patients? *

  4. What are the most common challenges you face in managing T2DM patients? (Select all that apply) *

  5. When intensifying treatment, which add-on to Metformin monotherapy is considered as providing the most durable glycemic control with minimal adverse effects? *

  6. In treatment-naïve type 2 diabetes patients with HbA1c levels between 8.0-10%, which of the following initial therapeutic regimens do you consider optimal? *

  7. For triple-drug therapy, which of the following Metformin-based regimens do you consider optimal for comprehensive glycemic and metabolic control? *

  8. How do you decide the choice of triple combination therapy? *

  9. What is the primary reason for choosing triple combination therapy of Metformin + Glimepiride + Sitagliptin? *

  10. In your experience, what has been the most effective approach to improving patient adherence to combination therapies in type 2 diabetes, especially when selecting three-drug fixed-dose combinations? *
  11. How do you manage patients who experience gastrointestinal side effects from metformin? *

  12. What is the most common side effect you observe with fixed dose combination of Metformin + Glimepiride + Sitagliptin? *

  13. In your experience, how long does it typically take to observe significant improvements in HbA1c after starting the Metformin + Glimepiride + Sitagliptin? *

  14. What strategies do you use to monitor and manage hypoglycemia in patients on Metformin + Glimepiride + Sitagliptin combination therapy? *

  15. How do you tailor the triple combination therapy to meet the individual needs of patients with different comorbidities or complications? *
  16. Please share your experience with triple combination therapy compared to dual combination in terms of efficacy and patient adherence? *

  17. What additional therapies do you consider if the triple combination therapy is insufficient? *

  18. How do you tailor the management of diabetes for elderly patients (>65 years of age) with respect to combination of Metformin + Glimepiride + Sitagliptin? (can select more than one options) *

  19. How do you decide when to switch from oral therapy to insulin in patients on this combination? (select as many as appropriate) *

  20. When managing diabetic patients with high cardiorenal risk, what combinations therapies do you prefer? And mention the reasons for the same *
  21. What strategies do you use to improve patient adherence to treatment regimens? (Select all that apply) *

  22. What is your overall satisfaction with the triple combination therapy of glimepiride, metformin, and sitagliptin in managing T2DM? *

  23. Please share long-term outcomes you have observed in patients using this triple combination therapy, particularly in terms of cardiovascular health and overall quality of life? *
  24. What are your thoughts on the future of oral antidiabetic therapies, and how do you see the role of triple combination therapies evolving in the management of T2DM? *
  25. How do you stay updated on the latest guidelines and research regarding this combination therapy? *